2AB
vs
D
DAX Index
2AB
Over the past 12 months, 2AB has underperformed DAX Index, delivering a return of -43% compared to the DAX Index's +15% growth.
Stocks Performance
2AB vs DAX Index
Performance Gap
2AB vs DAX Index
Performance By Year
2AB vs DAX Index
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Vaccitech PLC
Glance View
Vaccitech Plc operates as a holding company. The company is headquartered in Oxford, Oxfordshire and currently employs 72 full-time employees. The company went IPO on 2021-04-30. The firm is engaged in the discovery and development of immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer. The firm uses its platform to develop product candidates that target immune responses against pathogens and tumor cells. The firm has a pipeline of both clinical and preclinical stage therapeutic and prophylactic programs. Its therapeutic programs include VTP-300 for the treatment of chronic hepatitis B infection (CHB), VTP-200 for the treatment of human papilloma virus infection (HPV), VTP-850 for the treatment of prostate cancer and VTP-600 for the treatment of non-small cell lung cancer (NSCLC). Its prophylactic programs include VTP-400 for the prevention of herpes zoster (shingles), and VTP-500 for the prevention of the Middle East respiratory syndrome (MERS).